alglucosidase alfa

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Pompe Disease (Late-Onset)

Conditions

Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD-II), Glycogenesis Type II, Acid Maltase Deficiency (AMD)

Trial Timeline

Mar 1, 2007 → Nov 1, 2008

NCT ID

NCT00455195

About alglucosidase alfa

alglucosidase alfa is a approved stage product being developed by Sanofi for Pompe Disease (Late-Onset). The current trial status is completed. This product is registered under clinical trial identifier NCT00455195. Target conditions include Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD-II), Glycogenesis Type II.

What happened to similar drugs?

9 of 16 similar drugs in Pompe Disease (Late-Onset) were approved

Approved (9) Terminated (4) Active (6)

✅alglucosidase alfaSanofiApproved

✅Alglucosidase alfaSanofiApproved

✅alglucosidase alfaSanofiApproved

✅Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa)SanofiApproved

✅ALGLUCOSIDASE ALFASanofiApproved

✅alglucosidase alfa + alglucosidase alfaSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04676373	Approved	Completed	Mar 10, 2021	Jul 25, 2024	Pompe's Disease
NCT01710813	Pre-clinical	Completed	Mar 20, 2015	Apr 20, 2021	Pompe Disease
NCT01410890	Approved	Completed	Nov 3, 2014	Nov 20, 2020	Pompe Disease
NCT00566878	Pre-clinical	Completed	Mar 31, 2012	Feb 9, 2024	Glycogen Storage Disease
NCT01526785	Approved	Terminated	Mar 1, 2012	Dec 1, 2014	Pompe Disease
NCT01288027	Approved	Completed	Jun 1, 2011	Dec 1, 2013	Pompe Disease (Late-Onset)
NCT00486889	Approved	Completed	Aug 26, 2008	Nov 23, 2021	Pompe Disease
NCT00483379	Approved	Completed	May 1, 2007	Jul 1, 2010	Pompe Disease
NCT00455195	Approved	Completed	Mar 1, 2007	Nov 1, 2008	Pompe Disease (Late-Onset)
NCT00074919	Pre-clinical	Completed	Dec 1, 2003	Feb 1, 2007	Glycogen Storage Disease Type II
NCT00051935	Phase 2	Completed	Jan 1, 2003	Oct 1, 2003	Glycogen Storage Disease Type II

Competing Products

20 competing products in Pompe Disease (Late-Onset)

See all competitors

Product	Company	Stage	Hype Score
S-606001 + Placebo	Shionogi	Phase 2	42
GZ402666	Sanofi	Phase 1	29
alglucosidase alfa + Placebo	Sanofi	Phase 3	40
alglucosidase alfa	Sanofi	Approved	43
glucosidase alfa	Sanofi	Pre-clinical	26
Alglucosidase alfa	Sanofi	Approved	35
Avalglucosidase Alfa	Sanofi	Phase 2	35
alglucosidase alfa	Sanofi	Approved	43
Myozyme	Sanofi	Phase 3	40
alglucosidase alfa	Sanofi	Approved	43
alglucosidase alfa	Sanofi	Pre-clinical	26
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)	Sanofi	Phase 3	40
Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa)	Sanofi	Approved	35
ALGLUCOSIDASE ALFA	Sanofi	Approved	43
alglucosidase alfa + alglucosidase alfa	Sanofi	Approved	35
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)	Sanofi	Phase 2	39
Myozyme	Sanofi	Phase 2	35
Myozyme	Sanofi	Phase 2	35
recombinant human acid alpha-glucosidase (rhGAA)	Sanofi	Phase 2	35
Alglucosidase Alfa + Methotrexate + Rituximab	Sanofi	Approved	43